About Epsilon-sarcoglycan
Epsilon-sarcoglycan (SGCE) is a protein
from Homo sapiens identified by UniProt accession
O43556, 437 residues long.
MolForge cross-references it against 0 known binders and
165 disease associations.
Target properties
| Protein name | Epsilon-sarcoglycan |
| UniProt accession | O43556 |
| Gene | SGCE |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (165)
Diseases linked to this target (Open Targets).
- myoclonus-dystonia syndrome · score 0.67
- genetic disorder · score 0.47
- schizophrenia · score 0.27
- movement disorder · score 0.27
- breast carcinoma · score 0.26
- insomnia measurement · score 0.08
- Unverricht-Lundborg disease · score 0.07
- Progressive myoclonic epilepsy · score 0.07
- Familial cortical myoclonus · score 0.07
- myoclonus-cerebellar ataxia-deafness syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43556-F1 | alphafold | PREDICTED | 74.23 | — |
Amino-acid sequence (437 residues)
MQLPRWWELG DPCAWTGQGR GTRRMSPATT GTFLLTVYSI FSKVHSDRNV YPSAGVLFVH VLEREYFKGE FPPYPKPGEI SNDPITFNTN LMGYPDRPGW LRYIQRTPYS DGVLYGSPTA ENVGKPTIIE ITAYNRRTFE TARHNLIINI MSAEDFPLPY QAEFFIKNMN VEEMLASEVL GDFLGAVKNV WQPERLNAIN ITSALDRGGR VPLPINDLKE GVYVMVGADV PFSSCLREVE NPQNQLRCSQ EMEPVITCDK KFRTQFYIDW CKISLVDKTK QVSTYQEVIR GEGILPDGGE YKPPSDSLKS RDYYTDFLIT LAVPSAVALV LFLILAYIMC CRREGVEKRN MQTPDIQLVH HSAIQKSTKE LRDMSKNREI AWPLSTLPVF HPVTGEIIPP LHTDNYDSTN MPLMQTQQNL PHQTQIPQQQ TTGKWYP
Explore Epsilon-sarcoglycan with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets